Company intelligence / Profile preview

The Oncology Service

Leesburg, Virginia, United States

Ownership: Private
Employees: ~150
Development stage: Other

Overview

The Oncology Service (TOS) is a specialized veterinary healthcare provider focused exclusively on the diagnosis and treatment of cancer in companion animals. Operating as a network of specialty clinics, TOS provides advanced oncological care including medical oncology, radiation oncology, and stereotactic radiosurgery (SRS). The organization integrates clinical practice with veterinary clinical trials, offering pet owners access to cutting-edge therapies and investigational drugs. TOS is part of the Ethos Veterinary Health network, emphasizing a multidisciplinary approach to improve the quality of life for pets with cancer.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibodyRadiopharmaceuticalImmunotherapyChemotherapy
Industry: Veterinary

Partnerships

Ethos Discovery

Beyond the preview

Go deeper on The Oncology Service.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The Oncology Service.

Explore the full profile